On Tuesday, January 12, 2016, the Psychopharmacologic Drugs Advisory Committee (PDAC) supported, by a vote of 12-Yes to 5-No, with no abstentions, the safety and efficacy of PROBUPHINE (buprenorphine hydrochloride and ethylene vinyl acetate) subdermal implant, submitted by Braeburn Pharmaceuticals, Inc. on behalf of Titan Pharmaceuticals for the proposed indication of maintenance treatment of opioid dependence.